Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Prevention of allergy by virus-like nanoparticles (VNP) delivering shielded versions of major allergens in a humanized murine allergy model.

Kratzer B, Köhler C, Hofer S, Smole U, Trapin D, Iturri J, Pum D, Kienzl P, Elbe-Bürger A, Gattinger P, Mittermann I, Linhart B, Gadermaier G, Jahn-Schmid B, Neunkirchner A, Valenta R, Pickl WF.

Allergy. 2018 Jul 23. doi: 10.1111/all.13573. [Epub ahead of print]

PMID:
30035810
2.

Molecular Aspects of Allergens and Allergy.

Valenta R, Karaulov A, Niederberger V, Gattinger P, van Hage M, Flicker S, Linhart B, Campana R, Focke-Tejkl M, Curin M, Eckl-Dorna J, Lupinek C, Resch-Marat Y, Vrtala S, Mittermann I, Garib V, Khaitov M, Valent P, Pickl WF.

Adv Immunol. 2018;138:195-256. doi: 10.1016/bs.ai.2018.03.002. Epub 2018 Apr 26.

PMID:
29731005
3.

Genetic restriction of antigen-presentation dictates allergic sensitization and disease in humanized mice.

Neunkirchner A, Kratzer B, Köhler C, Smole U, Mager LF, Schmetterer KG, Trapin D, Leb-Reichl V, Rosloniec E, Naumann R, Kenner L, Jahn-Schmid B, Bohle B, Valenta R, Pickl WF.

EBioMedicine. 2018 May;31:66-78. doi: 10.1016/j.ebiom.2018.04.001. Epub 2018 Apr 5.

4.

Blocking antibodies induced by allergen-specific immunotherapy ameliorate allergic airway disease in a human/mouse chimeric model.

Vizzardelli C, Gindl M, Roos S, Möbs C, Nagl B, Zimmann F, Sexl V, Kenner L, Neunkirchner A, Zlabinger GJ, Pickl WF, Pfützner W, Bohle B.

Allergy. 2018 Apr;73(4):851-861. doi: 10.1111/all.13363. Epub 2017 Dec 22.

PMID:
29159964
5.

A cellular platform for the evaluation of immune checkpoint molecules.

Jutz S, Hennig A, Paster W, Asrak Ö, Dijanovic D, Kellner F, Pickl WF, Huppa JB, Leitner J, Steinberger P.

Oncotarget. 2017 May 4;8(39):64892-64906. doi: 10.18632/oncotarget.17615. eCollection 2017 Sep 12.

6.

Distinct epitope structures of defensin-like proteins linked to proline-rich regions give rise to differences in their allergenic activity.

Pablos I, Eichhorn S, Machado Y, Briza P, Neunkirchner A, Jahn-Schmid B, Wildner S, Soh WT, Ebner C, Park JW, Pickl WF, Arora N, Vieths S, Ferreira F, Gadermaier G.

Allergy. 2018 Feb;73(2):431-441. doi: 10.1111/all.13298. Epub 2017 Sep 27.

7.

Murine models for mucosal tolerance in allergy.

Smole U, Schabussova I, Pickl WF, Wiedermann U.

Semin Immunol. 2017 Apr;30:12-27. doi: 10.1016/j.smim.2017.07.007. Epub 2017 Aug 12. Review.

PMID:
28807539
8.

Rapid decline in insulin antibodies and glutamic acid decarboxylase autoantibodies with ibrutinib therapy of chronic lymphocytic leukaemia.

Skrabs C, Pickl WF, Perkmann T, Jäger U, Gessl A.

J Clin Pharm Ther. 2018 Feb;43(1):145-149. doi: 10.1111/jcpt.12602. Epub 2017 Jul 28.

PMID:
28753229
9.

The IL-10/STAT3 axis: Contributions to immune tolerance by thymus and peripherally derived regulatory T-cells.

Schmetterer KG, Pickl WF.

Eur J Immunol. 2017 Aug;47(8):1256-1265. doi: 10.1002/eji.201646710. Epub 2017 Jul 19. Review.

10.

MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy.

Colomer-Lahiguera S, Pisecker M, König M, Nebral K, Pickl WF, Kauer MO, Haas OA, Ullmann R, Attarbaschi A, Dworzak MN, Strehl S.

Leuk Lymphoma. 2017 Dec;58(12):2895-2904. doi: 10.1080/10428194.2017.1312383. Epub 2017 May 9.

PMID:
28482719
11.

Pharmacological targeting of allergen-specific T lymphocytes.

Tauber PA, Pickl WF.

Immunol Lett. 2017 Sep;189:27-39. doi: 10.1016/j.imlet.2017.03.010. Epub 2017 Mar 18. Review.

PMID:
28322861
12.

Chloroquine inhibits human CD4+ T-cell activation by AP-1 signaling modulation.

Schmidt RL, Jutz S, Goldhahn K, Witzeneder N, Gerner MC, Trapin D, Greiner G, Hoermann G, Steiner G, Pickl WF, Burgmann H, Steinberger P, Ratzinger F, Schmetterer KG.

Sci Rep. 2017 Feb 7;7:42191. doi: 10.1038/srep42191.

13.

RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics.

Salzer E, Cagdas D, Hons M, Mace EM, Garncarz W, Petronczki ÖY, Platzer R, Pfajfer L, Bilic I, Ban SA, Willmann KL, Mukherjee M, Supper V, Hsu HT, Banerjee PP, Sinha P, McClanahan F, Zlabinger GJ, Pickl WF, Gribben JG, Stockinger H, Bennett KL, Huppa JB, Dupré L, Sanal Ö, Jäger U, Sixt M, Tezcan I, Orange JS, Boztug K.

Nat Immunol. 2016 Dec;17(12):1352-1360. doi: 10.1038/ni.3575. Epub 2016 Oct 24.

PMID:
27776107
14.

On Peptides and Altered Peptide Ligands: From Origin, Mode of Action and Design to Clinical Application (Immunotherapy).

Candia M, Kratzer B, Pickl WF.

Int Arch Allergy Immunol. 2016;170(4):211-233. Epub 2016 Sep 20. Review.

15.

Creation of an engineered APC system to explore and optimize the presentation of immunodominant peptides of major allergens.

Rosskopf S, Jutz S, Neunkirchner A, Candia MR, Jahn-Schmid B, Bohle B, Pickl WF, Steinberger P.

Sci Rep. 2016 Aug 19;6:31580. doi: 10.1038/srep31580.

16.

[Guidelines for vaccination of immunocompromised individuals].

Wiedermann U, Sitte HH, Burgmann H, Eser A, Falb P, Holzmann H, Kitchen M, Köller M, Kollaritsch H, Kundi M, Lassmann H, Mutz I, Pickl WF, Riedl E, Sibilia M, Thalhammer F, Tucek B, Zenz W, Zwiauer K.

Wien Klin Wochenschr. 2016 Aug;128 Suppl 4:337-76. doi: 10.1007/s00508-016-1033-6. Epub 2016 Jul 25. German.

PMID:
27457874
17.

CD23 surface density on B cells is associated with IgE levels and determines IgE-facilitated allergen uptake, as well as activation of allergen-specific T cells.

Selb R, Eckl-Dorna J, Neunkirchner A, Schmetterer K, Marth K, Gamper J, Jahn-Schmid B, Pickl WF, Valenta R, Niederberger V.

J Allergy Clin Immunol. 2017 Jan;139(1):290-299.e4. doi: 10.1016/j.jaci.2016.03.042. Epub 2016 May 9.

18.

Years in Review: Recent Progress in Cellular Allergology.

Kratzer B, Pickl WF.

Int Arch Allergy Immunol. 2016;169(1):1-12. doi: 10.1159/000444753. Epub 2016 Mar 9. Review.

19.

The tryptophan metabolite picolinic acid suppresses proliferation and metabolic activity of CD4+ T cells and inhibits c-Myc activation.

Prodinger J, Loacker LJ, Schmidt RL, Ratzinger F, Greiner G, Witzeneder N, Hoermann G, Jutz S, Pickl WF, Steinberger P, Marculescu R, Schmetterer KG.

J Leukoc Biol. 2016 Apr;99(4):583-94. doi: 10.1189/jlb.3A0315-135R. Epub 2015 Oct 23.

PMID:
26497245
20.

CD8+ T Cell Fate and Function Influenced by Antigen-Specific Virus-Like Nanoparticles Co-Expressing Membrane Tethered IL-2.

Wojta-Stremayr D, Neunkirchner A, Srinivasan B, Trapin D, Schmetterer KG, Pickl WF.

PLoS One. 2015 May 6;10(5):e0126034. doi: 10.1371/journal.pone.0126034. eCollection 2015.

21.

Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity.

Ratzinger F, Haslacher H, Poeppl W, Hoermann G, Kovarik JJ, Jutz S, Steinberger P, Burgmann H, Pickl WF, Schmetterer KG.

Sci Rep. 2014 Dec 11;4:7438. doi: 10.1038/srep07438.

22.

CD19+CD21low B cells and CD4+CD45RA+CD31+ T cells correlate with first diagnosis of chronic graft-versus-host disease.

Greinix HT, Kuzmina Z, Weigl R, Körmoczi U, Rottal A, Wolff D, Kralj M, Kalhs P, Mitterbauer M, Rabitsch W, Edinger M, Holler E, Pickl WF.

Biol Blood Marrow Transplant. 2015 Feb;21(2):250-8. doi: 10.1016/j.bbmt.2014.11.010. Epub 2014 Nov 20.

23.

Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity.

Willmann KL, Klaver S, Doğu F, Santos-Valente E, Garncarz W, Bilic I, Mace E, Salzer E, Conde CD, Sic H, Májek P, Banerjee PP, Vladimer GI, Haskoloğlu S, Bolkent MG, Küpesiz A, Condino-Neto A, Colinge J, Superti-Furga G, Pickl WF, van Zelm MC, Eibel H, Orange JS, Ikincioğulları A, Boztuğ K.

Nat Commun. 2014 Nov 19;5:5360. doi: 10.1038/ncomms6360.

24.

STAT3 governs hyporesponsiveness and granzyme B-dependent suppressive capacity in human CD4+ T cells.

Schmetterer KG, Neunkirchner A, Wojta-Stremayr D, Leitner J, Steinberger P, Pickl WF.

FASEB J. 2015 Mar;29(3):759-71. doi: 10.1096/fj.14-257584. Epub 2014 Nov 14.

25.

Comprehensive comparative and semiquantitative proteome of a very low number of native and matched epstein-barr-virus-transformed B lymphocytes infiltrating human melanoma.

Maurer M, Müller AC, Parapatics K, Pickl WF, Wagner C, Rudashevskaya EL, Breitwieser FP, Colinge J, Garg K, Griss J, Bennett KL, Wagner SN.

J Proteome Res. 2014 Jun 6;13(6):2830-45. doi: 10.1021/pr401270y. Epub 2014 May 6.

PMID:
24803318
26.

Lymphocyte-based model systems for allergy research: a historic overview.

Neunkirchner A, Schmetterer KG, Pickl WF.

Int Arch Allergy Immunol. 2014;163(4):259-91. doi: 10.1159/000360163. Epub 2014 Apr 23. Review.

PMID:
24777172
27.

Early-onset inflammatory bowel disease and common variable immunodeficiency-like disease caused by IL-21 deficiency.

Salzer E, Kansu A, Sic H, Májek P, Ikincioğullari A, Dogu FE, Prengemann NK, Santos-Valente E, Pickl WF, Bilic I, Ban SA, Kuloğlu Z, Demir AM, Ensari A, Colinge J, Rizzi M, Eibel H, Boztug K.

J Allergy Clin Immunol. 2014 Jun;133(6):1651-9.e12. doi: 10.1016/j.jaci.2014.02.034. Epub 2014 Apr 17.

PMID:
24746753
28.

Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia.

Cerny-Reiterer S, Meyer RA, Herrmann H, Peter B, Gleixner KV, Stefanzl G, Hadzijusufovic E, Pickl WF, Sperr WR, Melo JV, Maeda H, Jäger U, Valent P.

Oncotarget. 2014 Mar 15;5(5):1198-211.

29.

A novel immunodeficiency syndrome associated with partial trisomy 19p13.

Seidel MG, Duerr C, Woutsas S, Schwerin-Nagel A, Sadeghi K, Neesen J, Uhrig S, Santos-Valente E, Pickl WF, Schwinger W, Urban C, Boztug K, Förster-Waldl E.

J Med Genet. 2014 Apr;51(4):254-63. doi: 10.1136/jmedgenet-2013-102122. Epub 2014 Jan 15.

30.

The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.

Peter B, Cerny-Reiterer S, Hadzijusufovic E, Schuch K, Stefanzl G, Eisenwort G, Gleixner KV, Hoermann G, Mayerhofer M, Kundi M, Baumgartner S, Sperr WR, Pickl WF, Willmann M, Valent P.

J Leukoc Biol. 2014 Jan;95(1):95-104. doi: 10.1189/jlb.1112609. Epub 2013 Sep 19.

PMID:
24052572
31.

CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance.

Putz EM, Gotthardt D, Hoermann G, Csiszar A, Wirth S, Berger A, Straka E, Rigler D, Wallner B, Jamieson AM, Pickl WF, Zebedin-Brandl EM, Müller M, Decker T, Sexl V.

Cell Rep. 2013 Aug 15;4(3):437-44. doi: 10.1016/j.celrep.2013.07.012. Epub 2013 Aug 8.

32.

Fluorosomes: fluorescent virus-like nanoparticles that represent a convenient tool to visualize receptor-ligand interactions.

Wojta-Stremayr D, Pickl WF.

Sensors (Basel). 2013 Jul 8;13(7):8722-49. doi: 10.3390/s130708722. Review.

33.

TIM-3 does not act as a receptor for galectin-9.

Leitner J, Rieger A, Pickl WF, Zlabinger G, Grabmeier-Pfistershammer K, Steinberger P.

PLoS Pathog. 2013 Mar;9(3):e1003253. doi: 10.1371/journal.ppat.1003253. Epub 2013 Mar 21.

34.

Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment.

Geusau A, Mothes-Luksch N, Nahavandi H, Pickl WF, Wise CA, Pourpak Z, Ponweiser E, Eckhart L, Sunder-Plassmann R.

JAMA Dermatol. 2013 Feb;149(2):209-15. doi: 10.1001/2013.jamadermatol.717.

PMID:
23426477
35.

B-cell deficiency and severe autoimmunity caused by deficiency of protein kinase C δ.

Salzer E, Santos-Valente E, Klaver S, Ban SA, Emminger W, Prengemann NK, Garncarz W, Müllauer L, Kain R, Boztug H, Heitger A, Arbeiter K, Eitelberger F, Seidel MG, Holter W, Pollak A, Pickl WF, Förster-Waldl E, Boztug K.

Blood. 2013 Apr 18;121(16):3112-6. doi: 10.1182/blood-2012-10-460741. Epub 2013 Jan 14.

36.

CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome.

Kuzmina Z, Krenn K, Petkov V, Körmöczi U, Weigl R, Rottal A, Kalhs P, Mitterbauer M, Ponhold L, Dekan G, Greinix HT, Pickl WF.

Blood. 2013 Mar 7;121(10):1886-95. doi: 10.1182/blood-2012-06-435008. Epub 2013 Jan 9.

37.

The value of identifying major T cell epitopes of clinically important allergens.

Pickl WF.

Int Arch Allergy Immunol. 2013;160(1):4-6. doi: 10.1159/000342422. Epub 2012 Aug 30. No abstract available.

38.

Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27.

Salzer E, Daschkey S, Choo S, Gombert M, Santos-Valente E, Ginzel S, Schwendinger M, Haas OA, Fritsch G, Pickl WF, Förster-Waldl E, Borkhardt A, Boztug K, Bienemann K, Seidel MG.

Haematologica. 2013 Mar;98(3):473-8. doi: 10.3324/haematol.2012.068791. Epub 2012 Jul 16.

39.

NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation.

Hadzijusufovic E, Peter B, Herrmann H, Rülicke T, Cerny-Reiterer S, Schuch K, Kenner L, Thaiwong T, Yuzbasiyan-Gurkan V, Pickl WF, Willmann M, Valent P.

Allergy. 2012 Jul;67(7):858-68. doi: 10.1111/j.1398-9995.2012.02833.x. Epub 2012 May 15.

40.

5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand.

Ghanim V, Herrmann H, Heller G, Peter B, Hadzijusufovic E, Blatt K, Schuch K, Cerny-Reiterer S, Mirkina I, Karlic H, Pickl WF, Zöchbauer-Müller S, Valent P.

Blood. 2012 May 3;119(18):4242-52. doi: 10.1182/blood-2011-09-382770. Epub 2012 Mar 21.

41.

Naturally occurring regulatory T cells: markers, mechanisms, and manipulation.

Schmetterer KG, Neunkirchner A, Pickl WF.

FASEB J. 2012 Jun;26(6):2253-76. doi: 10.1096/fj.11-193672. Epub 2012 Feb 23. Review.

PMID:
22362896
42.

Human TCR transgenic Bet v 1-specific Th1 cells suppress the effector function of Bet v 1-specific Th2 cells.

Neunkirchner A, Leb-Reichl VM, Schmetterer KG, Mutschlechner S, Kueng HJ, Haiderer D, Schuch K, Wallner M, Jahn-Schmid B, Bohle B, Pickl WF.

J Immunol. 2011 Oct 15;187(8):4077-87. doi: 10.4049/jimmunol.1003220. Epub 2011 Sep 9.

43.

The effects of Cyclosporine A and azathioprine on human T cells activated by different costimulatory signals.

Leitner J, Drobits K, Pickl WF, Majdic O, Zlabinger G, Steinberger P.

Immunol Lett. 2011 Oct 30;140(1-2):74-80. doi: 10.1016/j.imlet.2011.06.010. Epub 2011 Jul 2.

44.

KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.

Gleixner KV, Mayerhofer M, Cerny-Reiterer S, Hörmann G, Rix U, Bennett KL, Hadzijusufovic E, Meyer RA, Pickl WF, Gotlib J, Horny HP, Reiter A, Mitterbauer-Hohendanner G, Superti-Furga G, Valent P.

Blood. 2011 Aug 18;118(7):1885-98. doi: 10.1182/blood-2010-06-289959. Epub 2011 Jun 16.

45.

Interaction of allergens, major histocompatibility complex molecules, and T cell receptors: a 'ménage à trois' that opens new avenues for therapeutic intervention in type I allergy.

Jahn-Schmid B, Pickl WF, Bohle B.

Int Arch Allergy Immunol. 2011;156(1):27-42. doi: 10.1159/000321904. Epub 2011 Mar 29. Review.

PMID:
21447957
46.

Costimulatory signals potently modulate the T cell inhibitory capacity of the therapeutic CD11a antibody Efalizumab.

Kuschei WM, Leitner J, Majdic O, Pickl WF, Zlabinger GJ, Grabmeier-Pfistershammer K, Steinberger P.

Clin Immunol. 2011 May;139(2):199-207. doi: 10.1016/j.clim.2011.02.007. Epub 2011 Feb 10.

PMID:
21414849
47.

Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.

Peter B, Gleixner KV, Cerny-Reiterer S, Herrmann H, Winter V, Hadzijusufovic E, Ferenc V, Schuch K, Mirkina I, Horny HP, Pickl WF, Müllauer L, Willmann M, Valent P.

Haematologica. 2011 May;96(5):672-80. doi: 10.3324/haematol.2010.031328. Epub 2011 Jan 17.

48.

Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification.

Matutes E, Pickl WF, Van't Veer M, Morilla R, Swansbury J, Strobl H, Attarbaschi A, Hopfinger G, Ashley S, Bene MC, Porwit A, Orfao A, Lemez P, Schabath R, Ludwig WD.

Blood. 2011 Mar 17;117(11):3163-71. doi: 10.1182/blood-2010-10-314682. Epub 2011 Jan 12.

49.

Bet v 1-specific T-cell receptor/forkhead box protein 3 transgenic T cells suppress Bet v 1-specific T-cell effector function in an activation-dependent manner.

Schmetterer KG, Haiderer D, Leb-Reichl VM, Neunkirchner A, Jahn-Schmid B, Küng HJ, Schuch K, Steinberger P, Bohle B, Pickl WF.

J Allergy Clin Immunol. 2011 Jan;127(1):238-45, 245.e1-3. doi: 10.1016/j.jaci.2010.10.023.

PMID:
21211658
50.

Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease-associated dysgammaglobulinemia.

Kuzmina Z, Greinix HT, Weigl R, Körmöczi U, Rottal A, Frantal S, Eder S, Pickl WF.

Blood. 2011 Feb 17;117(7):2265-74. doi: 10.1182/blood-2010-07-295766. Epub 2010 Nov 9.

Supplemental Content

Loading ...
Support Center